Compensatory Smoking With Very Low Nicotine Content Cigarettes: A Systematic Review and Meta-Analysis - Takeaways - MDSpire

Compensatory Smoking With Very Low Nicotine Content Cigarettes: A Systematic Review and Meta-Analysis

  • By

  • Rachel L. Denlinger-Apte

  • Ziyu Ji

  • Emily A. Harwood

  • Darcy Lockhart

  • Neal L. Benowitz

  • Dana Mowls Carroll

  • Rachel N. Cassidy

  • Suzanne M. Colby

  • Eric C. Donny

  • Diann E. Gaalema

  • Brandy W. Hardy

  • Dorothy K. Hatsukami

  • Sarah H. Heil

  • Stephen T. Higgins

  • Xianghua Luo

  • F. Joseph McClernon

  • Stacey C. Sigmon

  • Tracy T. Smith

  • Andrew A. Strasser

  • Jennifer W. Tidey

  • David M. Vock

  • Cassidy M. White

  • Jack M. Wolf

  • Joseph S. Koopmeiners

  • July 15, 2026

Share

  • 1

    The FDA proposed a rule to establish a maximum nicotine level in cigarettes to reduce their addictiveness.

  • 2

    A modeling study suggested that a low nicotine policy could lead to nearly 5 million people quitting smoking in the first year.

  • 3

    Concerns exist about compensatory smoking with very low nicotine content cigarettes, which could lead to increased smoke exposure.

  • 4

    The study conducted a systematic review and meta-analysis to examine potential compensation in randomized clinical trials of VLNCs.

  • 5

    The analysis aimed to identify subgroups that may be more likely to compensate under a low-nicotine product standard.

Original Source(s)

Compensatory Smoking With Very Low Nicotine Content Cigarettes: A Systematic Review and Meta-Analysis

  • by Rachel L. Denlinger-Apte, Ziyu Ji, Emily A. Harwood, Darcy Lockhart, Neal L. Benowitz, Dana Mowls Carroll, Rachel N. Cassidy, Suzanne M. Colby, Eric C. Donny, Diann E. Gaalema, Brandy W. Hardy, Dorothy K. Hatsukami, Sarah H. Heil, Stephen T. Higgins, Xianghua Luo, F. Joseph McClernon, Stacey C. Sigmon, Tracy T. Smith, Andrew A. Strasser, Jennifer W. Tidey, David M. Vock, Cassidy M. White, Jack M. Wolf, Joseph S. Koopmeiners

  • July 15, 2026

Related Content

Reappraising traumatic brain injury and ventilator-associated pneumonia through the brain-lung-immune-microbiome axis

Fraxinellone mitigates acute lung injury by targeting HIF-1α to suppress pyroptosis and inflammation

Immunomodulation for stroke-associated pneumonia: a systematic review of mechanistic insight and emerging therapeutic strategies in animal models